Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 20,650 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listin.

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Karen Hunady - Director, IR and Corporate Communications Nancy Simonian - President and CEO David Roth - CMO Jason Haas - CFO Conley Chee - CCOO Conference Call Participants Ted Tenthoff - Piper Sandler Phil Nadeau - TD Cowen Operator Good morning, and welcome to Syros Pharmaceuticals' Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen only mode.

Syros Pharmaceuticals, Inc. (SYRS) Q2 2023 Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $5.40 per share a year ago.

Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “In the second quarter and recent months, we continued to focus on clinical execution, enrolling patients in our SELECT-AML-1 and SELECT-MDS-1 trials and advancing both studies toward data readou.

Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its second quarter 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 886-7786 (domestic) or (416) 764-8658 (internat.

Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Pfizer

Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therapies for two blood disorders.

Pfizer to end license deal with Syros for blood disorder therapies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 Virtual Small-Cap Conference. Management will also be available for one-on-one meetings. Details are as follows: Sidoti June 2023 Virtual Small-Cap Conference Date: Th.

Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced new clinical data from the Phase 1/1b clinical trial evaluating SY-5609, its highly selective and potent inhibitor of CDK7, in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumors. The data will be presented in two pos.

Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $4 per share a year ago.

Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update. “In 2023, we are focusing on clinical execution, with the goal of delivering tamibarotene and SY-2101 as new standards of care for the frontline treatment of hematologic malignancies,” said Nanc.

Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows: JMP Securities 2023 Life Sciences Conference Date: Tu.

Syros to Present at JMP Securities 2023 Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 886-7786 (domestic) or (416) 764-8658 (internati.

Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Karen Hunady - Director-Investor Relations & Corporate Communications Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Mark Breidenbach - Oppenheimer Jason Butler - JMP Securities Operator Good morning, and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Syros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.

Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March. Management will also be available for one-on-one meetings.

Syros to Participate in Upcoming Investor Conferences in March

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global myelodysplastic syndrome market is expected to reach $5.6 billion by 2032; 50% of high-risk MDS patients have RARA expression.

Syros: Multiple Shots On Goal In Blood Cancer Space

Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine for the treatment of newly diagnosed HR-MDS patients with RARA gene overexpression.

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS.

Syros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade)

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

Syros Announces Clinical Updates and 2023 Strategic Priorities

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy. These findings support Syros' ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome (MDS) patients with RARA overexpression. The paper, titled “Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML,” was published online in Blood Advances on December 7, 2022 at https://doi.org/10.1182/bloodadvances.2022008806.

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. The data is being presented today in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, LA.

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET.

News for Syros Pharmaceuticals Stock (SYRS)